{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-101817","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2025-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.630890+00:00","generated_at":"2026-05-17T02:29:47.227570+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verastem reports VS-7375 clears first two doses with tumor reduction in 4/5 evaluable patients","bullets":["No DLTs at 400 mg QD and 600 mg QD; no nausea/vomiting/diarrhea > Grade 1.","4 of 5 efficacy-evaluable patients had tumor reduction and remain on treatment.","Enrollment started for VS-7375 + cetuximab combo cohort in advanced solid tumors.","Interim safety/efficacy update expected in first half 2026.","Monotherapy dose escalation continues to 900 mg QD to select recommended Phase 2 dose."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-101817","json":"https://secwatch.observer/filing/0001104659-25-101817.json","markdown":"https://secwatch.observer/filing/0001104659-25-101817.md","text":"https://secwatch.observer/filing/0001104659-25-101817.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925101817/0001104659-25-101817-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925101817/tm2529362d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:29:47.227570+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}